BioSpace News Archive

Masimo will release fourth quarter results at Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

Enzolytics, Inc. (OTC PINK:ENZC) announced today the results of an in vitro study of the Companys ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity.

According to the World Health Organization, 13.6 percent of patients diagnosed with COVID-19 experienced a headache, often described as moderate to severe in intensity, many of which “may feel like a migraine attack.” Not only is headache one of the signs of the COVID-19 virus, it is also recognized as a lingering symptom long after the illness is over.

SquareWorks Consulting, a leading provider of NetSuite Consulting Services and NetSuite Solutions, is announcing the launch of Biotech-focused NetSuite implementation services.

-2021 Expected to be a Banner Year for Advancing Three Product Platforms in the Clinic: -Mino-Lok® Interim Efficacy Analysis -Halo-Lido filing IND and in Phase 2b trial -Mino-Wrap™ in Pre-Clinical Development, targeting IND by end of year

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company’s proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.

The CDC communicated that approximately 25.5 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced the pricing of the underwritten public offering of 2,197,803 of its ordinary shares for gross proceeds of approximately $10 million

New PhenoVue™ cell painting reagent kit makes the process of “painting” cells easier for research scientists by providing carefully selected and pre-optimized reagents

Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of strategic relationships with third parties, including regulatory authorities.